Taiwan study tracks fabry patients on enzyme therapy
NCT ID NCT06052800
First seen May 30, 2026 · Last updated Jun 20, 2026 · Updated 5 times
Summary
This study observes 78 adult Fabry disease patients in Taiwan who carry the GLA IVS4 mutation. It looks at how the enzyme replacement therapy agalsidase beta affects heart structure and other symptoms over time. The goal is to better understand the disease and treatment outcomes in this specific group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site Number : 1580001
Taipei, 100, Taiwan
-
Investigational Site Number : 1580002
Taipei, 112, Taiwan
-
Investigational Site Number : 1580003
Taipei, 104, Taiwan
-
Investigational Site Number : 1580004
Taichung, 407219, Taiwan
-
Investigational Site Number : 1580005
Tainan, 704, Taiwan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
agalsidase beta
What this could lead to
If successful, this study could provide clearer insights into how agalsidase beta affects heart health in Fabry patients with this specific mutation.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also limited to a specific mutation in Taiwan, so findings may not apply broadly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.